Results of a phase 2 study as a rationale for the BELIEVE study, a phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept in adult patients (Pts) requiring regular RBC transfusions due to β-Thalassemia (β-Thal)

The requested reference [dad7e44da6af212dea959801e6b64b5cc6980c2f] no longer exists in our database. It has been replaced by the current reference: [4262e9377fe36e531703a7bc975649e1c1359b9b]

Authors
Category Primary study
ConferenceOncology Research and Treatment
Year 2018
This article has no abstract
Epistemonikos ID: d402c26248310342c97422f4e70f192924be1fcf
First added on: Apr 29, 2026